[ad_1]
Fall Conference of Infectious Diseases Society, Korean Society for Antibacterial Therapy … CT-P59 Phase 1 Clinical Results Announced
The announcement that the Corona 19 treatment that Celltrion is developing has a therapeutic effect in mild patients was made in a Korean medical society.
On the 5th, Jin-yong Kim, an infectious medicine specialist at Incheon Medical Center, participated in the CT-P59 clinical trial. Announced.
In this clinical trial, three clinical trials in Korea and Europe evaluated the safety and tolerability of CT-P59, changes in clinical symptoms, and viral changes in 18 patients with early COVID-19 in three clinical trials. No abnormal cases were observed, confirming safety and tolerability, and it was confirmed that the mean time required to recover from symptoms after drug administration was reduced by 44% compared to the placebo group.
All patients who received CT-P59 recovered, but some of the placebo groups worsened. Most of the participants in this clinical trial were elderly and, unlike the placebo group, none of the patients who received CT-P59 developed serious disease.
In particular, as a result of administration of the drug to patients with high initial viral concentration, the virus decreased more rapidly than in the placebo group, indicating an early treatment effect through the antiviral effect of CT-P59.
Specialist Kim Jin-yong explained, “We were able to confirm that symptoms were actually alleviated when CT-P59 was administered to mild patients in the early stages of Corona 19, and we hope to be able to demonstrate the effect of CT-P59 in a clinical trial at large scale currently underway.
Celltrion announced that it will further accelerate the large-scale global clinical trial of CT-P59, a corona19 antibody treatment, based on successful clinical results.
A Celltrion official said: “Through this clinical outcome announced at the conference, we have confirmed the initial treatment effect of early administration of COVID-19 antibody treatment that the company has been emphasizing.” “Due to limitations, we will make every effort to provide CT-P59 early by accelerating the phase 2 clinical trials currently underway and obtaining results that meet the criteria.”
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited
